Madopar

Levodopa and Benserazide, the active ingredient in Madopar, is a dopamine precursor / dopa decarboxylase inhibitor combination presented as a oral tablet for oral use. It treats Parkinson's disease and Parkinsonian syndrome in adults.

GNH USA supplies Madopar as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Madopar is indicated for disorders of the dopaminergic system, primarily Parkinsonian conditions.

- Parkinson's disease: improves motor symptoms such as bradykinesia, rigidity and tremor. - Parkinsonian syndrome: alleviates motor deficits caused by secondary Parkinsonism. - Rest tremor associated with Parkinsonism: reduces tremor amplitude and frequency.

Adverse reactions may occur with Madopar use.

Common Side Effects: - Nausea - Vomiting - Orthostatic hypotension - Dyskinesia - Dry mouth - Drowsiness

Serious or Rare Side Effects: - Neuroleptic malignant‑like syndrome - Severe psychiatric reactions such as hallucinations or psychosis - Cardiac arrhythmias, including ventricular tachycardia - Hyperpyrexia - Severe allergic reactions (anaphylaxis)

Careful monitoring and individualized dosing are essential when prescribing Madopar.

- Dose titration: start low and increase gradually under medical supervision. - Cardiovascular monitoring: watch for hypotension and arrhythmias. - Psychiatric assessment: monitor for hallucinations or mood changes. - Renal/hepatic function: adjust dose if severe impairment is present. - Drug interactions: review concomitant medications for MAO‑B inhibitors. - Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Madopar can interact with several drug classes; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Antipsychotics (e.g., haloperidol): may reduce therapeutic effect. - High‑dose pyridoxine: may diminish levodopa absorption.

Moderate Interactions (Monitor Closely): - Antihypertensives: may enhance orthostatic hypotension. - Iron or calcium supplements: can reduce levodopa bioavailability. - SSRIs or SNRIs: may increase risk of serotonin syndrome.